罗格列酮对稳定性冠心病合并糖调节受损患者循环内皮祖细胞数量影响.docxVIP

上海交通大学硕士学位论文罗格列酮对稳定性冠心病合并糖调节受损患者循环内皮祖细胞数量的影响摘要目的：观察罗格列酮对稳定性冠心病合并糖调节受损患者循环内皮祖细胞（Endothelial progenitor cells, EPCs)数量的影响。方法：60例冠心病合并糖调节受损患者随机分为治疗组和对照组。两组均接受常规治疗，治疗组(30例)在常规治疗基础上给予罗格列酮 4mg/d,连续 12周。以 CD133/KDR作为 EPCs标记物，干预前后用流式细胞仪检测患者循环中 CD133/KDR双标记细胞的数量,同时检测代谢指标和 C-反应蛋白（CRP）。结果：(1)与基础值相比，治疗组经 12周干预后 BMI、FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL- C及 CRP均明显降低,P0.01；对照组 FPG、2hPG、LDL-C及 CRP降低，P0.05；12周后，两组循环 EPCs水平均升高，P0.05,与对照组相比，治疗组 EPCs水平升高4上海交通大学硕士学位论文更明显，P0.05；(2)相关分析显示，治疗组循环 EPCs改善值与HOMA-IR、FINS、TC和 LDL-C改善值呈负相关关系。结论：罗格列酮可以改善冠心病合并糖调节受损人群的胰岛素抵抗和糖脂代谢,增加循环EPCs的数量，具有潜在的心血管保护作用。关键词：罗格列酮,糖调节受损,冠心病,内皮祖细胞5上海交通大学硕士学位论文EFFECT OF ROSIGLITAZONE ON THE NUMBER OF CIRCULATINGENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH STABLECORONARY ARTERY DISEASE AND IMPAIRED GLUCOSEREGULATIONABSTRACTObjective：To observe the therapeutic efficacy of rosiglitazone onthe number of circulating endothelial progenitor cells（EPCs）in patientswith stable coronary artery disease and impaired glucose regulation(IGR).Methods: 60 consecutive patients with coronary artery disease andIGR were divided into study group and control group randomly. Bothreceived conventional therapy, while study group (30 cases) addedrosiglitazone 4mg/d for 12 weeks. Before and after intervention,metabolic parameters and C-reactive protein (CRP) were measured andcirculating EPCs as measured by the number of CD133/kinase insertdomain receptor (KDR) double positive cells were detected by FACS.Results: (1) Compared with basal value , after 12 weeks study group6上海交通大学硕士学位论文had a significant reduction in FPG、2hPG、FINS、HOMA - IR、CRP、TC、TG and LDL – C ,P0.01；Control group had a reduction in FPG、2hPG、LDL – C and CRP, P0.05；After 12 weeks both group had aincrease in the number of circulating EPCs , P0.05,While study grouphad a greater increase than control group, P0.05；(2) In the studygroup ,improving value of circulating EPCs was negatively correlatedwith improving value of HOMA-IR、FINS、TC and LDL– C.Conclusion: Rosiglitazone improved insulin res